Stéphane Pion
Direktor/Vorstandsmitglied bei PainCeptor Pharma Corp.
Aktive Positionen von Stéphane Pion
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Stéphane Pion
Ehemalige bekannte Positionen von Stéphane Pion
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Private-Equity-Analyst | 01.01.1998 | - |
Ausbildung von Stéphane Pion
| University of Montréal | Doctorate Degree |
Statistik
International
| Kanada | 4 |
Operativ
| Private Equity Analyst | 1 |
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
Sektoral
| Finance | 2 |
| Health Technology | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
- Börse
- Insiders
- Stéphane Pion
- Erfahrung
